MetaDisIDQ Kit

	Status	2011-05-18 sales start
	Organisation	Biocrates Life Sciences AG

Biocrates Life Sciences AG. (11/15/10). "Press Release: Austrian Biocrates Life Sciences AG Announces Launch of Its First Metabolomics-based Clinical Research Kit – MetaDisIDQ Kit".

Austrian BIOCRATES Life Sciences AG, a pioneer in the development of metabolic biomarker panels, announces the launch of its first clinical research kit product, the MetaDisIDQ Kit. With this latest addition to its product and services portfolio, the maker of the world’s first mass spectrometry–based metabolomics kits now provides additional derived parameters (sums and ratios) within the software for clinical research projects. Quantifying 181 metabolites from 5 compound classes, the MetaDisIDQ Kit is an excellent choice for clinical researchers in the area of diabetology and/or nutritional science looking for a cost-effective solution to quantify metabolites under quality-controlled conditions in their own laboratory.

BIOCRATES announces the launch of the latest addition to its products and services portfolio, the MetaDisIDQ Kit. The new kit developed by BIOCRATES, quantifies 181 metabolites from five compound classes, i.e., acylcarnitines, amino acids, phospho- and sphingolipids, hexoses, and biogenic amines. Not only does it deliver the widest available range of metabolomics information in a single assay, it also offers the same ease of identification and reliability of quantification already provided by its predecessors. Designed for use with AB Sciex API 4000™ or 4000 QTRAP® mass spectrometers, it enables researchers to measure all of their sensitive sample material and to analyze their proprietary data right in their own lab.

The BIOCRATES MetaDisIDQ Kit is a combined FIA-MS/MS and LC-MS/MS assay for robust and sensitive quantification. Quantification utilizes stable isotope-labeled or chemically homologous internal standards. The patented plate design ensures efficient sample derivatization and excellent reproducibility in analyte extraction. The assay is suitable for both manual and automated highthroughput operation and works with sample volumes as small as 10 µL.

The five compound classes analyzed by MetaDisIDQ Kit cover a wide range of relevant physiological events, and is especially designed for clinical research on metabolic disorders . It characterizes metabolic alterations in type II diabetes (T2D), the metabolic syndrome and its progression towards T2D as well as sequelae such as diabetic nephropathy. The kit also supports the assessment of antidiabetic drug efficacy. The MetIQ Software that ships with the kit streamlines data analysis, calculating metabolite concentrations in an automated manner and offering a number of output formats. Additionally, it provides sums and ratios relevant for (patho-)physiological phenomena, e.g. individual enzymatic activities, biologically related groups of metabolites, ratios reducing biological variability etc., and the manual contains a section describing the biochemical background of these parameters.

About BIOCRATES Life Sciences AG

Founded in 2002 in Innsbruck, Austria, BIOCRATES has dedicated its research activities to the youngest addition to the ‘omics’ quartet of systems biology, i.e., metabolomics, the study of the body’s small-molecule metabolites. The company’s research and development focus rests on the identification and validation of powerful biomarker panels that help identify disease risk, diagnose diseases, assess disease severity, and guide treatment and on the development of ‘companion diagnostics,’ i.e., biomarkers that help assess how a new drug works in the body and identify patients most likely to respond to a treatment.

For questions: Karoline Obitzhofer, BIOCRATES Life Sciences AG
Tel.: +43/512/579 823, e-mail: karoline.obitzhofer@biocrates.com

Record changed: 2011-11-27

Follow Us!

Top News

Upcoming Events

Associations

Partners

MetaDisIDQ Kit

Biocrates Life Sciences AG. (11/15/10). "Press Release: Austrian Biocrates Life Sciences AG Announces Launch of Its First Metabolomics-based Clinical Research Kit – MetaDisIDQ Kit".

More documents for drug discovery technology